...
首页> 外文期刊>Biochimica et Biophysica Acta. General Subjects >Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells
【24h】

Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells

机译:用于选择性靶向胰腺癌细胞的多官化氧化铁纳米粒子

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Nanomedicine nowadays offers novel solutions in cancer therapy by introducing multimodal treatments in one single formulation. In addition, nanoparticles act as nanocarriers changing the solubility, biodistribution and efficiency of the therapeutic molecules, thus generating more efficient treatments and reducing their side effects. To apply these novel therapeutic approaches, efforts are focused on the multi-functionalization of the nanoparticles and will open up new avenues to advanced combinational therapies. Pancreatic ductal adenocarcinoma (PDAC) is a cancer with unmet medical needs. Abundant expression of the anti-phagocytosis signal CD47 has also been observed on pancreatic cancer cells, in particular a subset of cancer stem cells (CSCs) responsible for resistance to standard therapy and metastatic potential. CD47 receptor is found on pancreatic cancer and highly expressed on CSCs, but not on normal pancreas. Inhibiting CD47 using monoclonal antibodies has been shown as an effective strategy to treat PDAC in vivo . However, CD47 inhibition effectively slowed tumor growth only in combination with Gemcitabine or Abraxane. In this work, we present the generation of multifunctionalized iron oxide magnetic nanoparticles (MNPs) that include the anti-CD47 antibody and the chemotherapeutic drug Gemcitabine in a single formulation. We demonstrate the in vitro efficacy of the formulation against CD47-positive pancreatic cancer cells. This article is part of a Special Issue entitled "Recent Advances in Bionanomaterials" Guest Editor: Dr. Marie-Louise Saboungi and Dr. Samuel D. Bader. Graphical abstract Display Omitted Highlights ? Multifunctional magnetic nanoparticles including therapeutic antibodies and drugs ? Controlled drug release system for selective treatment of pancreatic cancer cells ? Targeting CD47, a pancreatic cancer stem cell biomarker ? Effective targeting of functionalized MNPs to CD47-positive pancreatic cancer cells ? Efficient induction of apoptosis by the CD47 antibody and the cytotoxicity of the drug ]]>
机译:摘要Nanomedicine现在通过在一种单一制剂中引入多峰治疗来提供癌症疗法的新溶液。此外,纳米颗粒充当纳米载体改变治疗分子的溶解度,生物分布和效率,从而产生更有效的处理并降低它们的副作用。为了应用这些新颖的治疗方法,努力集中在纳米颗粒的多官能化上,并将新的途径开辟出高级组合疗法。胰腺导管腺癌(PDAC)是一种未满足医疗需求的癌症。在胰腺癌细胞上也观察到抗吞噬症信号CD47的丰富表达,特别是癌症干细胞(CSCs)的子集负责抵抗标准治疗和转移性潜力。 CD47受体在胰腺癌上发现并高表达CSC,但不是正常的胰腺。已经显示使用单克隆抗体抑制CD47作为治疗体内PDAC的有效策略。然而,CD47抑制仅与吉西他滨或阿布拉其共同有效地减缓了肿瘤生长。在这项工作中,我们介绍了在单一制剂中包括抗CD47抗体和化学治疗药物吉西他滨的多功能化氧化铁磁性纳米颗粒(MNP)的产生。我们证明了配方对CD47阳性胰腺癌细胞的体外效果。本文是题为“Bionanomaterials最近进步”的特殊问题的一部分,旨在编辑:Marie-Louise博士Saboungi和Samuel D博士。图形抽象显示省略了亮点?多官能磁性纳米粒子包括治疗抗体和药物吗?控制药物释放系统,用于胰腺癌细胞的选择性治疗?靶向CD47,胰腺癌干细胞生物标志物?有效靶向CD47阳性胰腺癌细胞的官能化MNPS? CD47抗体的高效诱导凋亡和药物的细胞毒性]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号